Figures and Tables
From the following article:
Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface
Timothy A. McKinsey & David A. Kass
Nature Reviews Drug Discovery 6, 617-635 (August 2007)
doi:10.1038/nrd2193
Figure 1
Targets for small-molecule drugs that modulate hypertrophic signalling.
Figure 2
Approaches to drug discovery for cardiac hypertrophy.
Figure 3
Rho/Rho kinase (ROCK) signalling and its potential role in hypertrophy.
Figure 4
mTOR signalling and its role in cardiac hypertrophy.
Figure 5
Reactive oxygen species (ROS) signalling in hypertrophy.
Figure 6
Small-molecule regulators of the cGMP/cGK1 (PKG1) pathway.
Figure 7
Small-molecule regulators of the cardiac calcineurin axis.
Figure 8
Repression of pathological cardiac genes by class IIa histone deacetylases.
Table 1
Compounds that have antihypertrophic activity in vivo*
Table 2
Compounds that have antihypertrophic activity in vivo*
